Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by J. A. Johnson
Total Records ( 2 ) for J. A. Johnson
  A. L Beitelshees , H Navare , D Wang , Y Gong , J Wessel , J. I Moss , T. Y Langaee , R. M Cooper DeHoff , W Sadee , C. J Pepine , N. J Schork and J. A. Johnson
 

Background— The gene encoding the target of calcium channel blockers, the 1c-subunit of the L-type calcium channel (CACNA1C), has not been well characterized, and only small pharmacogenetic studies testing this gene have been published to date.

Methods and Results— Resequencing of CACNA1C was performed followed by a nested case-control study of the INternational VErapamil SR/trandolapril STudy (INVEST) GENEtic Substudy (INVEST-GENES). Of 46 polymorphisms identified, 8 were assessed in the INVEST-GENES. Rs1051375 was found to have a significant interaction with treatment strategy (P=0.0001). Rs1051375 A/A genotype was associated with a 46% reduction in the primary outcome among those randomized to verapamil SR treatment, when compared with atenolol treatment (odds ratio 0.54 95% CI 0.32 to 0.92). In heterozygous A/G individuals, there was no difference in the occurrence of the primary outcome when randomized to verapamil SR versus atenolol treatment (odds ratio 1.47 95% CI 0.86 to 2.53), whereas homozygous G/G individuals had a greater than 4-fold increased risk of the primary outcome with verapamil treatment compared with those randomized to atenolol treatment (odds ratio 4.59 95% CI 1.67 to 12.67). We did not identify allelic expression imbalance or differences in mRNA expression in heart tissue by rs1051375 genotype.

Conclusions— Variation in CACNA1C is associated with treatment response among hypertensive patients with stable coronary artery disease. Our data suggest a genetically defined group of patients that benefit most from calcium channel blocker therapy, a group that benefits most from β-blocker therapy, and a third group in which calcium channel blocker and β-blocker therapy are equivalent.

  J. A. Johnson , S. U. Balko , G. Hugel , C. Low and L. W. Svenson
  Objective To compare recent trends of diabetes prevelance, incidence and mortality between men and women living in urban and rural Alberta, Canada. MethodsWe tracked population trends in diabetes in adults based on diagnostic codes from provincial administrative health records from 1995 to 2006. Location of residence was defined by registered postal codes. Sex-stratified logistic regression with interactions was used to compare increases in rates over the past decade by location of residence, adjusting for age. ResultsMen in rural residences had the greatest increases in prevalence, at 61%, from 3.6 per 100 in 1995 to 5.8 per 100 in 2006, compared with a 55% increase in urban men, from 3.9 per 100 in 1995 to 6.0 per 100 in 2006 (P<0.001). Diabetes incidence in rural men increased 61% while urban men had a similar increase of 59% (P=0.177). Incidence was lower in women in both urban and rural locations, at 5.6 and 5.3 per 1000 in 2006. Overall, mortality rates decreased by 34% for urban men and 8% for rural men with diabetes (P=0.006). Women with diabetes in rural areas had no decline in overall mortality, compared with a 28% reduction in urban women (P<0.001). ConclusionsDiabetes prevalence remains highest in men, with the greatest increases seen in men living in rural residences. While mortality rates have declined substantially over the past decade for those people with diabetes living in urban settings, declines in mortality in rural areas have been much more modest (for men) or non-existent (for women).
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility